KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $5.5 million.

  • Novavax's Interest Expenses rose 2941.45% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year increase of 4637.2%. This contributed to the annual value of $20.1 million for FY2024, which is 3925.5% up from last year.
  • Per Novavax's latest filing, its Interest Expenses stood at $5.5 million for Q3 2025, which was up 2941.45% from $5.5 million recorded in Q2 2025.
  • Novavax's 5-year Interest Expenses high stood at $7.6 million for Q4 2024, and its period low was $2.9 million during Q3 2023.
  • Moreover, its 5-year median value for Interest Expenses was $4.8 million (2021), whereas its average is $4.9 million.
  • In the last 5 years, Novavax's Interest Expenses crashed by 4988.77% in 2023 and then surged by 8423.61% in 2024.
  • Over the past 5 years, Novavax's Interest Expenses (Quarter) stood at $5.1 million in 2021, then fell by 10.45% to $4.6 million in 2022, then decreased by 10.52% to $4.1 million in 2023, then soared by 84.24% to $7.6 million in 2024, then fell by 27.73% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $5.5 million for Q2 2025, and $5.7 million during Q1 2025.